福泰制药Vertex Pharmaceuticals（VRTX）2024年10-K年度报告「NASDAQ」（英文版）（202页）.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the Fiscal Year Ended December 31,2024or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934FOR THE

2、TRANSITION PERIOD FROM TO Commission file number 000-19319Vertex Pharmaceuticals Incorporated(Exact name of registrant as specified in its charter)Massachusetts(State or other jurisdiction of incorporation or organization)50 Northern Avenue,Boston,Massachusetts(Address of principal executive offices

3、)04-3039129(I.R.S.Employer Identification No.)02210(Zip Code)Registrants telephone number,including area code(617)341-6100Securities registered pursuant to Section 12(b)of the Exchange Act:Title of Each ClassTrading SymbolName of Each Exchange on Which RegisteredCommon Stock,$0.01 Par Value Per Shar

4、eVRTXThe Nasdaq Global Select MarketSecurities registered pursuant to Section 12(g)of the Exchange Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file rep

5、orts pursuant to Section 13 or Section 15(d)of the Exchange Act.Yes No Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or forsuch shorter period that the registrant

6、 was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of this ch